Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 1001-1007

  Marconato, Laura ^a   Bettini, G ^b   Giacoboni, C ^a   Romanelli, G ^c   Cesari, A ^b   Zatelli, A ^d   Zini, E ^e  

^a Clinica Veterinaria L'Arca   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Clinica Veterinaria Nerviano   (Italy)

^d Clinica Veterinaria Pirani   (Italy)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Canine; Mastocytoma; Molecular targeted therapy; Systemic metastasis

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE MARROW CANCER; DOG; DOG DISEASE; METASTASIS; PATHOLOGY; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW NEOPLASMS; DOG DISEASES; DOGS; MAST-CELL SARCOMA;

ANIMALIA; CANIS FAMILIARIS;

EID: 47849119711     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0128.x     Document Type: Article

References (43)

1. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-41.
2. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumour: Morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
3. Thamm DH, Vail DM. Mast cell tumors. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's. Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: WB Saunders Co; 2007:402-424.
4. O'Keefe DA, Couto CG, Burke-Schwartz C, Jacobs RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med 1987;1:75-80.
5. Takahashi T, Kadosawa T, Nagase M, et al. Visceral mast cell tumors in dogs: 10 cases (1982-1997). J Am Vet Med Assoc 2000;216:222-226.
6. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology, 4th ed. Philadelphia, PA: WB Saunders; 2000:235-267.
7. Bookbinder PF, Butt MT, Harvey HJ. Determination of the number of mast cells in lymph node, bone marrow, and buffy coat cytologic specimens from dogs. J Am Vet Med Assoc 1992;200:1648-1650.
8. McManus PM. Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). J Am Vet Med Assoc 1999;215:355-357.
9. Pollack MJ, Flanders JA, Johnson RC. Disseminated malignant mastocytoma in a dog. J Am Anim Hosp Assoc 1991;27:435-440.
10. Davies AP, Hayden DW, Klausner JS, et al. Noncutaneous systemic mastocytosis and mast cell leukemia in a dog: Case report and literature review. J Am Anim Hosp Assoc 1981;17:361-368.
11. Lester SL, McGonigle LF, McDonald GK. Disseminated anaplastic mastocytoma with terminal mastocythemia in a dog. J Am Anim Hosp Assoc 1981;17:355-360.
12. Endicott MM, Charney SC, McKnight JA, et al. Clinico-pathological findings and results of bone marrow aspiration in dogs with cutaneous mast cell tumours: 157 cases (1999-2002). Vet Comp Onc 2007;5:31-37.
13. Weiss DJ. A retrospective study of the incidence and the classification of bone marrow disorders in the dog at a veterinary teaching hospital (1996-2004). J Vet Intern Med 2006;20:955-961.
14. Mullins MN, Dernell WS, Withrow SJ, et al. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 2006;228:91-95.
15. LaDue T, Price GS, Dodge R, et al. Radiation therapy for incompletely resected canine mast cell tumors. Vet Radiol Ultrasound 1998;39:57-62.
16. Spugnini EP, Vincenzi B, Baldi F, et al. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res 2006;26:4585-4589.
17. Frimberger AE, Moore AS, Cincotta L, et al. Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer. Clin Cancer Res 1998;4:2207-2218.
18. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor: 41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
19. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
20. Hayes A, Adams V, Smith K, et al. Vinblastine and prednis-olone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours. Vet Comp One 2007;5:168-176.
21. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004). Vet Comp One 2007;5:156-167.
22. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
23. Pryer NK, Lee LB, Zadovaskaya R, et al. Proof of target for SUl 1654: Inhibition of KIT phosphorylation in canine mast cell tumors. Clin Cancer Res 2003;9:5729-5734.
24. London CA, Hannah AL, Zadovoskaya R, et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clin Cancer Res 2003;9:2755-2768.
25. Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, et al. The role of c-KIT in tumorigenesis: Evaluation in canine cutaneous mast cell tumors. Neoplasia 2006;8:104-111.
26. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
27. Downing S, Chien MB, Kass PH, et al. Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs. Am J Vet Res 2002;63:1718-1723.
28. Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Vet Pathol 2002;39:529-535.
29. Webster JD, Kiupel M, Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer 2006;6:85-92.
30. Webster JD, Yuzbasiyan-Gurkan V, Miller RA, et al. Cellular proliferation in canine cutaneous mast cell tumors: Associations with c-KIT and its role in prognostication. Vet Pathol 2007;44:298-308.
31. Gleixner KV, Rebuzzi L, Mayerhofer M, et al. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Exp Hematol 2007;35:1510-1521.
32. London C. Kinase inhibitors in cancer therapy. Vet Comp Onc 2004;2:177-193.
33. Kobie K, Kawabata M, Hioki K, et al. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice. Res Vet Sci 2007;82:239-241.
34. Lachowicz JL, Post GS, Brodsky E. A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats. J Vet Intern Med 2005;19:860-864.
35. Isotani M, Tamura K, Yagihara H, et al. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate. Vet Immunol Immunopathol 2006;114:168-172.
36. Owen LN. TNM Classification of Tumors in Domestic Animals, 1st ed. Geneva, Switzerland: World Health Organization; 1980:7-15.
37. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukaemia. Clin Cancer Res 2002;8:935-942.
38. Veterinary Cooperative Oncology Group. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Vet Comp One 2004;2:194-213.
39. Eckersall PD, Nash AS. Isoenzymes of canine plasma alkaline phosphatase: An investigation using isoelectric focusing and related to diagnosis. Res Vet Sci 1983;34:310-314.
40. Webster JD, Kiupel M, Kaneene JB, et al. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Vet Pathol 2004;41:371-377.
41. Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc 2008;232:53-62.
42. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
43. Pegram MD, Konecny GE, O'Callaghan C, et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749.